PT - JOURNAL ARTICLE AU - Laurent P. Audoly AU - Lijun Ma AU - Igor Feoktistov AU - Stephanie K. de Foe AU - Matthew D. Breyer AU - Richard M. Breyer TI - Prostaglandin E-Prostanoid-3 Receptor Activation of Cyclic AMP Response Element-Mediated Gene Transcription DP - 1999 Apr 01 TA - Journal of Pharmacology and Experimental Therapeutics PG - 140--148 VI - 289 IP - 1 4099 - http://jpet.aspetjournals.org/content/289/1/140.short 4100 - http://jpet.aspetjournals.org/content/289/1/140.full SO - J Pharmacol Exp Ther1999 Apr 01; 289 AB - The prostaglandin E-prostanoid (EP)3 receptor signals primarily through the inhibitory G protein Gi, thereby decreasing intracellular cAMP levels. To study the signal transduction properties of the rabbit EP3 receptor, five splice variants were expressed in HEK293tsA201 cells: 72A, 74A, 77A, 80A and the novel splice variant NT, which lacks the C-terminal sequence. The ability of the EP3 receptor splice variants to modulate expression of a β-galactosidase reporter gene under the control of a promoter containing cAMP response elements (CRE) was assessed. Each splice variant induced sulprostone-mediated increase in β-galactosidase enzymatic activity with EC50 ranging from 0.8 nM for the NT splice variant to 3.1 nM for the 77A splice variant. Substitution of either Asp338 with Ala, or Arg329 with Ala or Glu in the 77A splice variant resulted in a loss of receptor-evoked increases in β-galactosidase activity, whereas substitution of Lys300 with alanine had no effect on signal transduction. These phenotypes correlate with the inhibition of cAMP generation by direct cAMP measurement. Signal transduction was insensitive to pretreatment of cells with pertussis toxin, suggesting that a nonGi/Go pathway is activated by the EP3 receptor. Direct measurement of second messenger levels confirmed that there was no increase in cAMP levels mediated by the 77A splice variant, however, there was a modest increase in intracellular Ca2+. Partial blockade of the reporter activity with kinase inhibitors demonstrates that CRE activation is mediated in part by a Ca2+-dependent kinase pathway. These data suggest that the EP3 receptor signals through a novel cAMP response element binding protein/CRE pathway. The American Society for Pharmacology and Experimental Therapeutics